Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries

Abstract Background Different treatment modalities are available for obesity management, including lifestyle changes, pharmacotherapy, endoscopic interventions, and surgeries. Limited evidence is available on the weight loss effect of combining glucagon-like peptide 1 receptor agonists (GLP-1 RAs) w...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Endocrine Society Vol. 7; no. 12; p. bvad129
Main Authors: Imam, Ahmad, Alim, Hussam, Binhussein, Mohammad, Kabli, Abdulrahman, Alhasnani, Husam, Allehyani, Abdullah, Aljohani, Ammar, Mohorjy, Ahmad, Tawakul, Abdullah, Samannodi, Mohammed, Taha, Wael
Format: Journal Article
Language:English
Published: US Oxford University Press 01-12-2023
Subjects:
Comparative analysis
Drug therapy
Glucagon
Homeopathy
Liraglutide
Lorcaserin
Materia medica and therapeutics
Obesity
Surgery
Therapeutics
Type 2 diabetes
Weight loss
bariatric surgeries
liraglutide
weight loss
GLP-1 receptor agonist
endoscopic bariatric therapy
obesity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Different treatment modalities are available for obesity management, including lifestyle changes, pharmacotherapy, endoscopic interventions, and surgeries. Limited evidence is available on the weight loss effect of combining glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with endoscopic bariatric therapy (EBT) and bariatric surgeries (BS). Objectives In this systematic review, we compared the weight loss effect and metabolic changes of combining GLP-1 RAs with EBT and BS. Methods Literature searches were performed in the Cochrane Database of Systematic Review, Cochrane Central Register of Controlled Trials, Embase, PubMed, Google Scholar, and PRISMA databases. Only randomized control trials and retrospective studies were included. Results A total of 11 studies was included. Nine studies compared BS with and without liraglutide and 2 compared EBT with and without liraglutide. Adding liraglutide to EBT or BS provided significant weight loss when compared with EBT or BS alone. When changes in weight were compared across the studies, EBT with liraglutide showed a weight loss effect comparable to the net weight loss (ie, nadir weight loss after BS-regained weight) achieved following BS alone. Conclusion This review showcases a promising approach for managing obesity that combines GLP-1 RAs with EBT. This approach is expected to achieve shorter hospital stays, fewer side effects, and longer term weight loss benefits than BS alone. However, additional prospective studies with higher quality, more consistent outcome measures for weight loss and metabolic changes are needed to further evaluate the approach.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2472-1972
2472-1972
DOI:10.1210/jendso/bvad129